PMID- 17017186
OWN - NLM
STAT- MEDLINE
DCOM- 20110407
LR  - 20140625
VI  - 20
IP  - 14
DP  - 2006 Jul
TI  - [Multivariate survival analysis in patient with laryngeal squamous cell 
      carcinomas].
PG  - 636-9
AB  - OBJECTIVE: This study was designed to analyze the most important factors 
      affecting the prognosis of the patients with laryngeal squamous cell carcinoma 
      (LSCC). METHOD: The expression of S-phase kinase associated protein 2(Skp2), p27, 
      E-cadherin (E-cad) and alpha-catenin (alpha-cat) in 79 cases of LSCC and 10 cases 
      of adjacent normal laryngeal mucosa tissues were evaluated by SP 
      immunohistochemistry methods, 12 clinicopathological factors affecting the 
      prognosis of LSCC were analyzed using univariate model and multivariate 
      regression model. RESULT: (1) The overexpression rate of Skp2 was significantly 
      higher in LSCC (53.16%) than in adjacent normal laryngeal mucosa tissue (0%) (P < 
      0.05). The overexpression rate of p27 was significantly lower in LSCC (30.38%) 
      than in adjacent normal laryngeal mucosa tissue (90%) (P < 0.05). The positive 
      expression rate of E-cad was significantly lower in LSCC (34.18%) than in 
      adjacent normal laryngeal mucosa tissue (100%) (P < 0.05). The positive 
      expression rate of alpha-cat was significantly lower in LSCC (40.51%) than in 
      adjacent normal laryngeal mucosa tissue (100%) (P < 0.05). (2) There was a 
      significantly higher 5-year survival rate in reduced Skp2 expression group 
      (72.18%) when compared with that of Skp2 overexpression group (44.17%) in LSCC (P 
      < 0.01). There was a significantly higher 5-year survival rate in p27 
      overexpression group (72.98%) when compared with that of reduced p27 expression 
      group in LSCC (51.13%) (P < 0.01). The 5-year survival rates of positive E-cad 
      expression group and positive alpha-cat expression group in LSCC were 63.80% and 
      81.74% respectively, the 5-year survival rates of negative E-cad expression group 
      and negative alpha-cat expression group were 50.68% and 41.09% respectively. 
      There were significantly higher 5-year survival rates in positive expression 
      groups when compared with that of negative expression groups (P < 0.05 and P < 
      0.01). (3) The univariate analysis showed: histology grade, status of cervical 
      lymph node, clinical stage, T stage, recurrence, Skp2 expression, p27 expression, 
      E-cad expression and alpha-cat expression were proven to significant (P < 0.05); 
      Multivariate analysis showed: Skp2 expression, alpha-cat expression and 
      recurrence were independent prognostic factors of survival of LSCC patients (P < 
      0.05). (4) Skp 2 expression was inversely associated with p27 expression, p27 
      expression was significantly associated with alpha-cat expression, E-cad 
      expression was significantly associated with alpha-cat expression. CONCLUSION: 
      The chief prognostic factors of survival of LSCC patients were Skp2 expression, 
      alpha-cat expression and recurrence.
FAU - Guo, Jianfeng
AU  - Guo J
AD  - Department of Otolaryngology, Dongguan People's Hospital, Dongguan 523018, China.
FAU - Chen, Fujin
AU  - Chen F
FAU - Guan, Zhiwei
AU  - Guan Z
FAU - Chen, Yanfeng
AU  - Chen Y
FAU - Li, Qiuli
AU  - Li Q
FAU - Ouyang, Dian
AU  - Ouyang D
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Lin Chuang Er Bi Yan Hou Ke Za Zhi
JT  - Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
JID - 9426080
RN  - 0 (Cadherins)
RN  - 0 (S-Phase Kinase-Associated Proteins)
RN  - 0 (alpha Catenin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cadherins/metabolism
MH  - Carcinoma, Squamous Cell/diagnosis/*metabolism/mortality
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/diagnosis/*metabolism/mortality
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - S-Phase Kinase-Associated Proteins/metabolism
MH  - Survival Rate
MH  - alpha Catenin/metabolism
EDAT- 2006/10/05 09:00
MHDA- 2011/04/08 06:00
CRDT- 2006/10/05 09:00
PHST- 2006/10/05 09:00 [pubmed]
PHST- 2011/04/08 06:00 [medline]
PHST- 2006/10/05 09:00 [entrez]
PST - ppublish
SO  - Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Jul;20(14):636-9.